Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease..
J Clin Gastroenterol. 46(4), 272-84.
(2012). Juvenile Paget disease..
Metabolism. 80, 15-26.
(2018). Alterations in serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review..
Thyroid. 20(3), 265-71.
(2010). Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study..
Arq Gastroenterol. 51(3), 261-8.
(2014). Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis..
Metabolism. 154203.
(2020). Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review..
Expert Rev Endocrinol Metab. 5(5), 673-679.
(2010). Leptin in nonalcoholic fatty liver disease: a narrative review..
Metabolism. 64(1), 60-78.
(2015). Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations..
Aliment Pharmacol Ther.
(2021). Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid..
Endokrynol Pol. 63(4), 312-5.
(2012). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas..
Int J Clin Pract. 65(3), 373-4.
(2011). Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease..
Endocrine. 49(2), 560-2.
(2015). Periostin and sclerostin levels in juvenile Paget's disease..
Clin Cases Miner Bone Metab. 14(2), 269-271.
(2017). Adult hypophosphatasia treated with reduced frequency of teriparatide dosing..
J Musculoskelet Neuronal Interact. 21(4), 584-589.
(2021). Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer..
Hormones (Athens).
(2022). Irisin: A true, circulating hormone..
Metabolism. 64(12), 1611-8.
(2015). Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease..
Metabolism. 61(6), 755-8.
(2012). Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease..
Metabolism. 147, 155676.
(2023). Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity..
Hepatobiliary Surg Nutr. 9(1), 73-76.
(2020). Nonalcoholic fatty liver disease in males with low testosterone concentrations..
Diabetes Metab Syndr. 14(5), 1571-1577.
(2020). Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis.
Current Medicinal Chemistry. 30,
(2023). Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns..
Metabolism. 104, 154144.
(2020). Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?.
Metabolism. 96, iii-v.
(2019). Sarcopenic obesity..
Hormones (Athens). 17(3), 321-331.
(2018). The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease..
Diabetes Obes Metab. 12(5), 365-83.
(2010).